clinical trial · NCT07444307
A Clinical Study of Dual-Target, Universal CAR-T Cell Therapy for Refractory Systemic Lupus Erythematosus
Hangzhou Qihan Biotech Co., Ltd.·phase1·recruiting·n = 18
Systemic Lupus Erythematosus (SLE)QT-019B Cell Injection
brief summary
This study is a single-arm, open-label clinical study designed to evaluate the safety and tolerability of QT-019B in subjects with refractory SLE and to determine the RD. The study has two phases: dose escalation and dose expansion, with a planned enrollment of 18-24 subjects.
started
Dec 15, 2025
primary completion
Dec 31, 2028
completion
Dec 31, 2028
last updated
Mar 2, 2026
official title
A Phase I/IIa Clinical Study to Evaluate Universal Allogeneic CAR-T Cells (QT-019B) Targeting CD19 and BCMA for the Treatment of Refractory Systemic Lupus Erythematosus
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol